<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02129660</url>
  </required_header>
  <id_info>
    <org_study_id>DRM04-HH02</org_study_id>
    <nct_id>NCT02129660</nct_id>
  </id_info>
  <brief_title>Comparator Study of the Effect of DRM04B and DRM 04 in Subjects With Axillary Hyperhidrosis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind Vehicle-Controlled Comparator Study of the Effect of DRM04B and DRM04 in Subjects With Axillary Hyperhidrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermira, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety of 2 doses of DRM04B compared to 2 doses of
      DRM04 and vehicle (5 treatment arms) for the treatment of axillary hyperhidrosis when applied
      once daily for 4 weeks followed by a 2-week post-dose period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, vehicle controlled, parallel group, comparator study
      designed to assess the safety, efficacy and pharmacokinetics of two doses of DRM04B compared
      to two doses of DRM04 compared to vehicle, 5 treatment arms.

      Efficacy will be assessed through gravimetric assessment of sweat production using Patient
      Reported Outcome and the Hyperhidrosis Disease Severity Score (HDSS).

      Safety will be assessed through adverse events, local skin responses, serum chemistry and
      hematology laboratory testing, ECGs, physical examination and vital signs.

      PK blood samples will be taken study subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Not provided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who have a minimum 2-grade improvement in HDSS from Baseline at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Not provided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in the gravimetrically measured sweat production from Baseline to Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Not provided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in the gravimetrically measured sweat production from Baseline to Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Not provided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Not provided</description>
  </primary_outcome>
  <other_outcome>
    <measure>Patient Reported Outcome absolute change in the questions from Baseline to Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Not provided</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcome change in the questions from Baseline to Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Not provided</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcome Shift tables comparing Baseline to Week 4 and Week 6 for each treatment group</measure>
    <time_frame>Week 6</time_frame>
    <description>Not provided</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcome change in the question 6 from Baseline to Week 4 and Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Not provided</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcome exploratory PK/PD relationships will be assessed</measure>
    <time_frame>Week 6</time_frame>
    <description>Not provided</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>Dose 1 of DRM04B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRM04B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 of DRM04B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRM04B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1 of DRM04</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DRM04</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 of DRM04</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DRM04</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 1 of DRM04B</intervention_name>
    <arm_group_label>Dose 1 of DRM04B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 2 of DRM04B</intervention_name>
    <description>Not provided</description>
    <arm_group_label>Dose 2 of DRM04B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 1 of DRM04</intervention_name>
    <description>Not provided</description>
    <arm_group_label>Dose 1 of DRM04</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 2 of DRM04</intervention_name>
    <arm_group_label>Dose 2 of DRM04</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 years of age or older.

          -  Primary, axillary hyperhidrosis of at least 6 months duration.

          -  Hyperhidrosis Disease Severity Score (HDSS) of 3 or 4 at baseline.

          -  For each axilla, a baseline gravimetric measurement of sweat production of at least 50
             mg over 5 minutes, while at rest, at room temperature.

          -  Male or non-pregnant, non-lactating females.

        Exclusion Criteria:

          -  Current pregnancy or lactation.

          -  Prior surgical procedure for hyperhidrosis.

          -  Any prior axillary treatment with an anti-hyperhidrosis medical device

          -  Any prior treatment with an investigational drug within 4 weeks prior to Baseline/Day
             1 or within 5 elimination half lives of the active agent, whichever is longer or 6
             weeks if the elimination half life is not known. Experimental devices are excluded
             without the approval of the Medical Monitor.

          -  Prior treatment with botulinum toxin (e.g., BotoxÂ®) for axillary hyperhidrosis within
             1 year of Baseline/Day 1.

          -  Subjects with clinically significant abnormalities in laboratory values.

          -  Subjects with a positive Hepatitis or HIV.Hepatitis B surface antibody positive is
             allowed only if the subject has a history of having received Hepatitis B vaccination
             and there are no clinically significant abnormalities in screening liver function
             tests.

          -  Treatment with cholinergic, serotonergic antagonists, and dopamine partial agonists
             thought to relieve antidepressant-induced hyperhidrosis, within one month prior to
             Baseline/Day 1.

          -  Treatment with psychotherapeutic medications for less than 4 months prior to
             Baseline/Day 1.

          -  Treatment with topical or systemic anticholinergics, adrenergic agonists (clonidine),
             or beta-blockers within 4 weeks of the baseline visit

          -  Prior treatment with axillary iontophoresis within 4 weeks of Baseline/Day 1.

          -  Any previous IV or oral treatment with the study drug.

          -  Prior treatment with the topical study drug in a previous trial.

          -  Axillary use of nonprescription or prescription antiperspirants within 2 weeks of
             study enrollment.

          -  Presence of a condition, within 10 years of enrollment, that may cause secondary
             hyperhidrosis

          -  Menopausal women who have had symptoms of menopause such as sweating or flushing
             within 3 years of the study may not be enrolled.

          -  Known history of SjÃ¶gren's syndrome or Sicca syndrome.

          -  History of glaucoma, inflammatory bowel disease, toxic megacolon, or febrile illness.

          -  Men with a history of urinary retention requiring catheterization due to prostatic
             hypertrophy or severe obstructive symptoms of prostatic hypertrophy.

          -  Abnormal findings on screening ECG deemed clinically significant by the Investigator.

          -  History or presence of ventricular arrhythmias, atrial fibrillation, atrial flutter.
             History of other supraventricular tachycardia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynne M. Deans, MT</last_name>
    <role>Study Director</role>
    <affiliation>Dermira, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Dermatology &amp; Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Dermatology Clinical Research</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenneth R. Beer MD</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shideler Clinical Research Center</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Dermatology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haber Dermatology and Cosmetic Surgery</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivergate Dermatology Clinical Research Center, PLLC</name>
      <address>
        <city>Goodlettsville 37072</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Clinical Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc.</name>
      <address>
        <city>Montreal</city>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2014</study_first_posted>
  <disposition_first_submitted>October 22, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>October 22, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 13, 2015</disposition_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

